Valor202020212022202320242025TTMGastos comerciales, generales y administrativos14.2 B14.89 B14.25 B12.52 B12.57 B13.25 B—Investigación y desarrollo8.98 B9.54 B10 B11.37 B10.02 B11.2 B—Beneficio operativo10.15 B11.69 B9.2 B9.77 B14.54 B17.64 B—Total de ingresos no operativos———————Gastos por intereses, netos de intereses capitalizados———————Ingresos no operativos, una vez deducidos los gastos por intereses———————Ingresos/gastos extraordinarios———————Beneficio antes de impuestos9.88 B26.14 B2.38 B596 M3.54 B329 M—Participación en los beneficios———————Impuestos1.81 B2.12 B1.42 B551 M1.7 B2.38 B—Participación minoritaria1 M3 M04 M2 M17 M—Otros ingresos/gastos después de impuestos———————Beneficio neto antes de actividades interrumpidas3.48 B19.43 B6.96 B8.57 B5.66 B7.68 B—Operaciones suspendidas4.59 B4.59 B—6.28 B6.28 B6.28 B—Beneficio neto8.07 B24.02 B6.96 B14.85 B11.94 B13.97 B—Ajuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas———————Beneficio básico por acción———————Beneficio por acción diluido———————Número medio de acciones ordinarias———————Acciones diluidas———————EBITDA———————EBIT———————Costo de los ingresos15.12 B15.87 B15.49 B12.47 B12.83 B13.7 B—Otros costes de producción———————Amortización y depreciación (flujo de caja)———————
Novartis AG
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024.
Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others.
Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes.
After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz.